These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3778545)

  • 1. Successful treatment of autoimmunity in MRL/1 mice with LS-2616, a new immunomodulator.
    Tarkowski A; Gunnarsson K; Nilsson LA; Lindholm L; Stålhandske T
    Arthritis Rheum; 1986 Nov; 29(11):1405-9. PubMed ID: 3778545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of LS-2616 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice.
    Tarkowski A; Gunnarsson K; Stålhandske T
    Immunology; 1986 Dec; 59(4):589-94. PubMed ID: 3804379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of immunomodulating treatment on cutaneous delayed-type hypersensitivity in MRL lpr/lpr mice.
    Carlsten H; Tarkowski A; Nilsson LA
    APMIS; 1989 Aug; 97(8):728-32. PubMed ID: 2788441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of immunomodulating treatment on autoimmune sialadenitis in MRL/Mp-lpr/lpr mice.
    Jonsson R; Tarkowski A; Bäckman K
    Agents Actions; 1988 Dec; 25(3-4):368-74. PubMed ID: 3218611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunomodulator Linomide: role in treatment and prevention of autoimmune diabetes mellitus.
    Gross DJ; Weiss L; Reibstein I; Hedlund G; Dahlén E; Rapoport MJ; Slavin S
    Int Immunopharmacol; 2001 Jun; 1(6):1131-9. PubMed ID: 11407307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma.
    Kalland T
    Cancer Res; 1986 Jun; 46(6):3018-22. PubMed ID: 3486041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amelioration of intrathymic T cell development and peripheral T cell reactivities in autoimmune mice undergoing therapy with a novel immunomodulator.
    Spetz-Hagberg AL; Goldschmidt TJ; Stålhandske T; Larsson-Sciard EL
    Int Immunol; 1990; 2(7):645-50. PubMed ID: 2278995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased levels of pathogenic IgG anti-DNA antibodies in autoimmune mice after linomide treatment.
    Spetz-Hagberg AL; Larsson-Sciard EL
    Res Immunol; 1989; 140(5-6):517-25. PubMed ID: 2789418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of CD28/CTLA4-B7 costimulatory pathway in the development of lymphadenopathy and splenomegaly in MRL/lpr mice.
    Takiguchi M; Murakami M; Nakagawa I; Rashid MM; Tosa N; Chikuma S; Hashimoto A; Uede T
    J Vet Med Sci; 2000 Jan; 62(1):29-36. PubMed ID: 10676886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of a new immunomodulator oxo-quinoline-3-carboxamide on the progression of experimental lupus.
    Carlsten H; Jonsson C; Bokarewa M; Svensson L; Tarkowski A
    Int Immunopharmacol; 2004 Nov; 4(12):1515-23. PubMed ID: 15351320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune glomerulonephritis induced in congenic mouse strain carrying telomeric region of chromosome 1 derived from MRL/MpJ.
    Ichii O; Konno A; Sasaki N; Endoh D; Hashimoto Y; Kon Y
    Histol Histopathol; 2008 Apr; 23(4):411-22. PubMed ID: 18228198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide.
    Karussis DM; Lehmann D; Slavin S; Vourka-Karussis U; Mizrachi-Koll R; Ovadia H; Ben-Nun A; Kalland T; Abramsky O
    Ann Neurol; 1993 Nov; 34(5):654-60. PubMed ID: 8239559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Linomide on immune cells and cytokines inhibit autoimmune pathologies of the central and peripheral nervous system.
    Hedlund G; Link H; Zhu J; Xiao BG
    Int Immunopharmacol; 2001 Jun; 1(6):1123-30. PubMed ID: 11407306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of experimental systemic lupus erythematosus with linomide.
    Zandman-Goddard G; George J; Levy Y; Blank M; Slavin S; Shoenfeld Y
    Lupus; 1996 Aug; 5(4):328-33. PubMed ID: 8869907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic determinants of autoimmune disease and coronary vasculitis in the MRL-lpr/lpr mouse model of systemic lupus erythematosus.
    Gu L; Weinreb A; Wang XP; Zack DJ; Qiao JH; Weisbart R; Lusis AJ
    J Immunol; 1998 Dec; 161(12):6999-7006. PubMed ID: 9862736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe tissue trauma triggers the autoimmune state systemic lupus erythematosus in the MRL/++ lupus-prone mouse.
    Anam K; Amare M; Naik S; Szabo KA; Davis TA
    Lupus; 2009 Apr; 18(4):318-31. PubMed ID: 19276300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alteration in progression of murine autoimmune disease by treatment with a novel immunomodulator, SM-8849.
    Nishikaku F; Koga Y
    Int J Immunopharmacol; 1991; 13(5):445-54. PubMed ID: 1783457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunomodulating therapy of adjuvant disease in rats].
    Sibiriak SV; Lazareva DN; Khaĭbullina SF
    Farmakol Toksikol; 1988; 51(2):72-4. PubMed ID: 3378610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CS-A therapy in MRL-lpr/lpr mice: amelioration of immunopathology despite autoantibody production.
    Mountz JD; Smith HR; Wilder RL; Reeves JP; Steinberg AD
    J Immunol; 1987 Jan; 138(1):157-63. PubMed ID: 3537128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel autoimmune pancreatitis model in MRL mice treated with polyinosinic:polycytidylic acid.
    Qu WM; Miyazaki T; Terada M; Okada K; Mori S; Kanno H; Nose M
    Clin Exp Immunol; 2002 Jul; 129(1):27-34. PubMed ID: 12100019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.